Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030524 · ClinicalTrials.gov registry record · Phase 2
ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00030524: Completed Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
NCT00030524 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at San Antonio. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00030524, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of colorectal cancer. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have locally advanced or metastatic colorectal cancer that has not responded to chemotherapy.
Interventions
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01 |
| Est. Completion | 2003-09 |
| Phase | Phase 2 |
What the finished NCT00030524 record still lists
NCT00030524 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which gefitinib is the first listed.
NCT00030524 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00030524 about?
NCT00030524 is a clinical study titled "ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer". RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of colorectal cancer. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have locally advanced or metastatic colorectal cancer that has not responded ...
What is the current status of trial NCT00030524?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-01. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00030524?
The interventions under investigation include: gefitinib (DRUG).
Who is sponsoring clinical trial NCT00030524?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia